parallel to the American trials discussed in the previous article on the interview of Prof. Fasano, Canada Dr. Richard Fedorak, professor specializing in gastroenterology 's University of Alberta, is conducting a' Other research on the effects of Larazati (Larazotide Acetate, which is the AT1001 or pill for celiac disease). It
news from the CTV National News in Toronto, Canada, in an article in the March 7, 2010, linked by a video [1].
interview Dr. Fedorak said the encouraging results that the drug is gaining in patients who have undergone the trial.
But what is striking is that these trials showed that the drug might even help repair the intestinal tissue already damaged.
And look at the difference in tissue sections by electron microscopy in the video of CTV.ca, one might be surprised.
Also in this article emphasizes that there is a care, but a valuable pharmacological help to protect the intestinal walls in case of ingestion of sporadic (and not excessive) amounts of gluten (eg. how many times we wanted to eat a piece of pizza or a sandwich on a trip with the other ?).
Appare evidente che il mondo scientifico si sta interessando particolarmente a questo tipo di soluzione, non solo perché è in grado di evitare la reazione autoimmune nei celiaci, ma per le altre implicazioni che a cui il farmaco potrebbe portare.
Pensiamo ad eventuali sperimentazioni su altre patologie, non solo varianti della Celiachia (es. la Celiachia Refrattaria), ma anche altri disordini immuno-mediati.
L’articolo conclude con un frase del direttore esecutivo dell’Associazione Celiachia Canadese, Jim McCarthy: “E’ incoraggiante sapere che ci possono essere terapie alternative, oltre che una stretta dieta senza glutine”.
0 comments:
Post a Comment